dacarbazine has been researched along with erythrosine in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Aftab, Q; Chen, VC; Gielen, PR; Hong, X; Lozinsky, S; Ma, N; Naus, CC; Sin, WC | 1 |
| Munoz, JL; Rameshwar, P; Scotto, KW; Walker, ND | 1 |
2 other study(ies) available for dacarbazine and erythrosine
| Article | Year |
|---|---|
Connexin43 confers Temozolomide resistance in human glioma cells by modulating the mitochondrial apoptosis pathway.
Topics: Analysis of Variance; Annexin A5; Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Connexin 43; Cytochromes c; Dacarbazine; Dose-Response Relationship, Drug; Fluoresceins; Glioma; Humans; Mitochondria; Mutation; Phosphorylation; RNA, Small Interfering; Signal Transduction; Temozolomide; Time Factors; Transfection | 2013 |
Temozolomide competes for P-glycoprotein and contributes to chemoresistance in glioblastoma cells.
Topics: Animals; Antineoplastic Agents, Alkylating; ATP Binding Cassette Transporter, Subfamily B; Binding, Competitive; Brain Neoplasms; Caspase 3; Cell Line, Tumor; Cricetinae; Dacarbazine; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Fluoresceins; Gene Expression Regulation, Neoplastic; Glioblastoma; Humans; Temozolomide; Transcription, Genetic; Transcriptional Activation; Transfection; Up-Regulation | 2015 |